Athersys Receives a Buy from Maxim Group

By Jason Carr

In a report released today, Jason Kolbert from Maxim Group maintained a Buy rating on Athersys (NASDAQ: ATHX), with a price target of $6. The company’s shares closed yesterday at $1.56.

Kolbert noted:

“Summary Athersys issued a press release this morning ahead of their scheduled earnings release and conference call tonight. News is that the company will significantly expand their existing development and commercialization collaboration with partner Healios (6927JP – ¥998 – NR). Healios will make a ~$21M equity investment at $1.76 per share, a premium to Athersys current share price of $1.56. Specifics mentioned:.”

According to, Kolbert is ranked 0 out of 5 stars with an average return of -5.7% and a 37.7% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and Arbutus Biopharma Corporation.

Athersys has an analyst consensus of Moderate Buy, with a price target consensus of $6.

Based on Athersys’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $399K and GAAP net loss of $7.24 million. In comparison, last year the company earned revenue of $983K and had a GAAP net loss of $7.13 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.